5
Jim Davis
Chairman, CEO, and President
2022 – Present
4 years (current)
Legacy
Davis assumed CEO role in November 2022 and became Chairman in April 2023. He has accelerated the acquisition strategy (LifeLabs, Spectra Laboratories, numerous hospital outreach deals), advanced the AD-Detect Alzheimer's testing platform, industrialized Haystack Oncology MRD testing, and expanded consumer-initiated testing through QuestDirect. He raised 2026 guidance and increased the dividend 7.5% in 2026. This ensures long-term success. This ensures long-term success. Yes.